Literature DB >> 670706

Kinetic assessment of alternative complement pathway activity in a hemolytic system. II. Influence of antibody on alternative pathway activation.

R B Polhill, S L Newman, K M Pruitt, R B Johnston.   

Abstract

By using a kinetic assay, we have examined the role of antibody in the lysis of rabbit erythrocytes (RaRBC) through the alternative complement (C) pathway. Sera from some hypogammaglobulinemic (Hgamma) humans and all agammaglobulinemic chickens tested had subnormal activity in the assay. Heated normal human or chicken sera, but not heated Hgamma sera, restored activity to deficient Hgamma serum and initiated hemolysis in the presence of rabbit serum as C source. Absorption of heated normal human serum with RaRBC, but not with sheep erythrocytes or zymosan, removed its ability to reconstitute deficient Hgamma serum. Normal hemolytic activity could be resotred to Hgamma serum with human IgM, IgG, or colostral IgA, with goat anti-RaRBC IgG, or with an eluate from serum-sensitized RaRBC, but not with myeloma IgA. Restoration of hemolytic activity to Hgamma serum could be achieved in a dose-dependent fashion with the F(ab')2 fragment of IgG. These results suggest that antibody exerts a significant rate-limiting effect on alternative pathway activity in the RaRBC lytic system. This raises the possibility that antibody may be required for efficient alternative pathway activity in vivo and that the pyogenic infections that occur in Hgamma individuals are due to inefficient activation and fixation of C3 through either the classical or alternative pathway.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 670706

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans.

Authors:  M A Wilson; T R Kozel
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

2.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

3.  Activation of the alternative complement pathway by natural antibody to glycolipids in guinea-pig serum.

Authors:  N Okada; T Yasuda; T Tsumita; H Okada
Journal:  Immunology       Date:  1983-09       Impact factor: 7.397

4.  Serum IgG levels and complement activity in hypogammaglobulinaemic patients under substitution therapy.

Authors:  A Plebani; L D Notarangelo; M Duse; A Avanzini; M Massa; A G Ugazio
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

Review 5.  The role of antibody in the activation of the alternative complement pathway.

Authors:  W D Ratnoff; D T Fearon; K F Austen
Journal:  Springer Semin Immunopathol       Date:  1983

6.  Vibrio vulnificus (lactose-positive vibrio) and Vibrio parahaemolyticus differ in their susceptibilities to human serum.

Authors:  M M Carruthers; W J Kabat
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

7.  Contrasting roles of mannan-specific monoclonal immunoglobulin M antibodies in the activation of classical and alternative pathways by Candida albicans.

Authors:  M X Zhang; J E Cutler; Y Han; T R Kozel
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

8.  Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae.

Authors:  D E Briles; M Nahm; K Schroer; J Davie; P Baker; J Kearney; R Barletta
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

9.  [Problems of intravenous gammaglobulin therapy (author's transl)].

Authors:  J Ring; K H Duswald
Journal:  Klin Wochenschr       Date:  1980-08-15

10.  Role of anti-pilus antibodies in host defense against gonococcal infection studied with monoclonal anti-pilus antibodies.

Authors:  M Virji; J E Heckels
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.